Sanket Koul

All stories by Sanket Koul

Half of India Faces Glucose Imbalance

Half of India Faces Glucose Imbalance

Rediff.com5 Dec 2024

'Obesity, especially central obesity and increased visceral fat due to physical inactivity, along with the consumption of high-calorie, high-fat, and high-sugar diets, are major contributing factors.'

What's Driving Surge in Breast Cancer?

What's Driving Surge in Breast Cancer?

Rediff.com1 Nov 2024

Late-stage diagnosis is a major issue, with over 75 per cent of cases being detected at advanced stages (50 per cent at Stage 3 and 25 per cent at Stage 4). This significantly reduces survival rates.

Now, Karnataka Wants To Scrap NEET

Now, Karnataka Wants To Scrap NEET

Rediff.com26 Jul 2024

Karnataka has the highest number of medical seats in the country at 11,745, of which 3,750 seats were in government institutions and 7,995 seats were in private colleges.

How To Fix Ayushman Bharat: Experts To FM

How To Fix Ayushman Bharat: Experts To FM

Rediff.com28 Jun 2024

'Patients under the scheme may ultimately have to go to private hospitals.'

NEET-PG Delay May Push Doctors Abroad

NEET-PG Delay May Push Doctors Abroad

Rediff.com24 Jun 2024

'The NEET-PG is the only exam for admission to MD, MS and PG Diploma courses.' 'Many doctors take time off from work to prepare for it, while others study during their long hospital shifts.'

52% Of Urban Indians Utilise Ayush

52% Of Urban Indians Utilise Ayush

Rediff.com18 Jun 2024

Ayush refers to the six Indian systems of medicines, namely Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa-Rigpa and Homeopathy are majorly prevalent in the country.

Expanding Ayushman Bharat On Cards

Expanding Ayushman Bharat On Cards

Rediff.com15 Jun 2024

The move to expand the health insurance scheme's coverage comes at a time when several hospitals have complained of delays in reimbursement related to the procedures performed under the scheme.

Modi 3.0's Plans For Ayushman Bharat

Modi 3.0's Plans For Ayushman Bharat

Rediff.com12 Jun 2024

The Centre is considering a proposal on increasing coverage under the Ayushman Bharat scheme to Rs 10 lakh from the current Rs 5 lakh.

'Fortis plans to add 700 beds in FY25'

'Fortis plans to add 700 beds in FY25'

Rediff.com12 Jun 2024

'Our priority remains brownfield expansion, and in the next few years, we plan to increase our capacity to around 6,000 beds.'

AyushMin gets rap for underuse of funds despite rising allocation

AyushMin gets rap for underuse of funds despite rising allocation

Rediff.com27 Feb 2024

Given the gap between budgetary allocation and use, a parliamentary standing committee has asked the Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (Ayush) to take steps to prevent underutilisation of funds under the National Ayush Mission (NAM) scheme. According to the data, the ministry was allocated Rs 1,200 crore for the mission in the Budgetary Estimate (BE) for FY24. The Revised Estimate (RE) for the year fell to Rs 815 crore, of which Rs 589 crore, or 74 per cent, has been spent till January.

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Rediff.com20 Nov 2023

Pharmaceuticals major Mankind Pharma reported a 21 per cent year-on-year (Y-o-Y) increase in net profit, with revenue rising by 12 per cent Y-o-Y in the second quarter of the financial year 2024 (Q2FY24) in a regulatory filing lrecently.

IKS Health, backed by Jhunjhunwala family, buys US tech firm for Rs 1,600 cr

IKS Health, backed by Jhunjhunwala family, buys US tech firm for Rs 1,600 cr

Rediff.com1 Nov 2023

AQuity Solutions is a leading tech-enabled clinical documentation, medical coding and revenue integrity solutions provider in the healthcare domain. On the other hand, IKS Health provides administrative, clinical and operational services to clinicians.

Israel conflict unlikely to impact trade of pharma firms

Israel conflict unlikely to impact trade of pharma firms

Rediff.com12 Oct 2023

Indian pharmaceutical firms foresee minimal disruptions in trade with Israel despite escalating regional tensions. Rising crude prices and export shipping insurance premiums have raised concerns, but the pharmaceutical sector remains optimistic. Pharmaceutical exports from India to Israel in FY 2020-21 amounted to $32.5 million, which represents only a minor segment of India's overall pharma exports.